{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:25:07Z","timestamp":1789831507047,"version":"4.0.1"},"reference-count":57,"publisher":"Impact Journals, LLC","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,3,29]]},"DOI":"10.18632\/oncotarget.7751","type":"journal-article","created":{"date-parts":[[2016,2,26]],"date-time":"2016-02-26T19:18:55Z","timestamp":1456514335000},"page":"17162-17181","source":"Crossref","is-referenced-by-count":9,"title":["ER maleate is a novel anticancer agent in oral cancer: implications for cancer therapy"],"prefix":"10.18632","volume":"7","author":[{"given":"Guodong","family":"Fu","sequence":"first","affiliation":[{"name":"Department of Medicine, Alex and Simona Shnaider Research Laboratory in Molecular Oncology, Endocrine Division, Mount Sinai Hospital, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj Thani","family":"Somasundaram","sequence":"additional","affiliation":[{"name":"Department of Medicine, Alex and Simona Shnaider Research Laboratory in Molecular Oncology, Endocrine Division, Mount Sinai Hospital, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Jessa","sequence":"additional","affiliation":[{"name":"Department of Medicine, Alex and Simona Shnaider Research Laboratory in Molecular Oncology, Endocrine Division, Mount Sinai Hospital, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Medicine, Alex and Simona Shnaider Research Laboratory in Molecular Oncology, Endocrine Division, Mount Sinai Hospital, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"MacMillan","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Witterick","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2014 Head and Neck Surgery, Joseph and Mildred Sonshine Family Centre for Head and Neck Diseases, Mount Sinai Hospital, Toronto, Canada"},{"name":"Department of Otolaryngology \u2014 Head and Neck Surgery, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Walfish","sequence":"additional","affiliation":[{"name":"Department of Medicine, Alex and Simona Shnaider Research Laboratory in Molecular Oncology, Endocrine Division, Mount Sinai Hospital, Toronto, Canada"},{"name":"Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada"},{"name":"Department of Otolaryngology \u2014 Head and Neck Surgery, Joseph and Mildred Sonshine Family Centre for Head and Neck Diseases, Mount Sinai Hospital, Toronto, Canada"},{"name":"Department of Medicine, Endocrine Division, Mount Sinai Hospital and University of Toronto, Toronto, Canada"},{"name":"Department of Otolaryngology \u2014 Head and Neck Surgery, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranju","family":"Ralhan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Alex and Simona Shnaider Research Laboratory in Molecular Oncology, Endocrine Division, Mount Sinai Hospital, Toronto, Canada"},{"name":"Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada"},{"name":"Department of Otolaryngology \u2014 Head and Neck Surgery, Joseph and Mildred Sonshine Family Centre for Head and Neck Diseases, Mount Sinai Hospital, Toronto, Canada"},{"name":"Department of Otolaryngology \u2014 Head and Neck Surgery, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,2,26]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Bray","year":"2015","journal-title":"Int J Cancer"},{"key":"2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.oraloncology.2008.01.006","article-title":"Recent advances in Oral Oncology 2007: imaging, treatment and treatment outcomes","volume":"44","author":"Bagan","year":"2008","journal-title":"Oral Oncol"},{"key":"3","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(08)60728-X","article-title":"Head and neck cancer","volume":"371","author":"Ferris","year":"2008","journal-title":"Lancet"},{"key":"4","first-page":"318145","article-title":"Prevention and early detection of head and neck squamous cell cancers","volume":"2011","author":"Sankaranarayanan","year":"2011","journal-title":"J Oncol"},{"key":"5","first-page":"145","article-title":"Head and Neck: Squamous cell carcinoma: an overview","volume":"16","author":"Audrey","year":"2012","journal-title":"Atlas Genet Cytogenet Oncol Haematol"},{"key":"6","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.ijrobp.2008.05.024","article-title":"Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers","volume":"73","author":"Lee","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2407-6-28","article-title":"A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck","volume":"6","author":"Dietz","year":"2006","journal-title":"BMC Cancer"},{"key":"8","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2005.01.057","article-title":"Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group","volume":"23","author":"Forastiere","year":"2005","journal-title":"J Clin Oncol"},{"key":"9","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/j.ijrobp.2007.04.088","article-title":"Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update","volume":"69","author":"Bourhis","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl 10","key":"10","first-page":"x178","article-title":"Locally advanced head and neck squamous cell cancer: treatment choice based on risk factors and optimizing drug prescription","volume":"23","author":"Siu","year":"2012","journal-title":"Ann Oncol"},{"key":"11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.semradonc.2008.09.009","article-title":"Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond","volume":"19","author":"Grandis","year":"2009","journal-title":"Semin Radiat Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/CCO.0b013e3282f9b575","article-title":"Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck","volume":"20","author":"Siu","year":"2008","journal-title":"Curr Opin Oncol"},{"key":"13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1758-3284-1-6","article-title":"Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma","volume":"1","author":"Ralhan","year":"2009","journal-title":"Head Neck Oncol"},{"key":"14","doi-asserted-by":"crossref","first-page":"e61555","DOI":"10.1371\/journal.pone.0061555","article-title":"DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells","volume":"8","author":"Brakenhoff","year":"2013","journal-title":"PLoS One"},{"key":"15","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/j.molonc.2015.05.005","article-title":"Anticancer activity of pyrithione zinc in oral cancer cells identified in small molecule screens and xenograft model: Implications for oral cancer therapy","volume":"9","author":"Ralhan","year":"2015","journal-title":"Mol Oncol"},{"key":"16","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.tips.2014.05.007","article-title":"Getting Syk: spleen tyrosine kinase as a therapeutic target","volume":"35","author":"Geahlen","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"17","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1158\/0008-5472.CAN-14-0629","article-title":"SYK is a candidate kinase target for the treatment of advanced prostate cancer","volume":"75","author":"Snaar-Jagalska","year":"2015","journal-title":"Cancer Res"},{"key":"18","doi-asserted-by":"crossref","first-page":"7907","DOI":"10.1158\/0008-5472.CAN-07-0331","article-title":"Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck","volume":"67","author":"Eccles","year":"2007","journal-title":"Cancer Res"},{"key":"19","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrm2653","article-title":"Polo-like kinases: conservation and divergence in their functions and regulation","volume":"10","author":"Glover","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"key":"20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature07185","article-title":"Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery","volume":"455","author":"Medema","year":"2008","journal-title":"Nature"},{"key":"21","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1158\/1078-0432.CCR-09-1380","article-title":"Targeting Polo-like kinase in cancer therapy","volume":"16","author":"Lampkin","year":"2010","journal-title":"Clin Cancer Res"},{"key":"22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/2162-3619-1-38","article-title":"Polo-like kinase 1 as target for cancer therapy","volume":"1","author":"Efferth","year":"2012","journal-title":"Exp Hematol Oncol"},{"key":"23","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s10637-015-0223-9","article-title":"Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity","volume":"33","author":"Schoffski","year":"2015","journal-title":"Invest New Drugs"},{"key":"24","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1038\/bjc.2014.195","article-title":"A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies","volume":"110","author":"Yang","year":"2014","journal-title":"Br J Cancer"},{"key":"25","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/CAD.0000000000000007","article-title":"Current clinical trials with polo-like kinase 1 inhibitors in solid tumors","volume":"24","author":"Yim","year":"2013","journal-title":"Anticancer Drugs"},{"key":"26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/2040620715571077","article-title":"Targeting polo-like kinase 1 in acute myeloid leukemia","volume":"6","author":"Brandwein","year":"2015","journal-title":"Ther Adv Hematol"},{"key":"27","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1124\/jpet.114.221150","article-title":"Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia","volume":"352","author":"Moll","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"28","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-08-2445","article-title":"BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity","volume":"15","author":"Adolf","year":"2009","journal-title":"Clin Cancer Res"},{"key":"29","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1038\/sj.onc.1210355","article-title":"Rational combinations of siRNAs targeting Plk1 with breast cancer drugs","volume":"26","author":"Strebhardt","year":"2007","journal-title":"Oncogene"},{"key":"30","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrd3184","article-title":"Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy","volume":"9","author":"Strebhardt","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"31","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.1158\/0008-5472.CAN-14-1916","article-title":"Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer","volume":"74","author":"Liu","year":"2014","journal-title":"Cancer Res"},{"key":"32","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1074\/jbc.M607609200","article-title":"Nitric oxide down-regulates polo-like kinase 1 through a proximal promoter cell cycle gene homology region","volume":"282","author":"Danner","year":"2007","journal-title":"J Biol Chem"},{"key":"33","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1158\/0008-5472.CAN-08-4252","article-title":"Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia","volume":"69","author":"Zirlik","year":"2009","journal-title":"Cancer Res"},{"key":"34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ccell.2015.05.009","article-title":"Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules","volume":"28","author":"Shih Ie","year":"2015","journal-title":"Cancer Cell"},{"key":"35","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nature10733","article-title":"A novel retinoblastoma therapy from genomic and epigenetic analyses","volume":"481","author":"Shurtleff","year":"2012","journal-title":"Nature"},{"key":"36","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nsmb.2040","article-title":"Alternative splicing of SYK regulates mitosis and cell survival","volume":"18","author":"Perreault","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"37","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/JID.2015.381","article-title":"Spleen Tyrosine Kinase Mediates EGFR Signaling to Regulate Keratinocyte Terminal Differentiation","volume":"136","author":"Lin","year":"2016","journal-title":"J Invest Dermatol"},{"key":"38","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccr.2006.10.012","article-title":"Che-1 phosphorylation by ATM\/ATR and Chk2 kinases activates p53 transcription and the G2\/M checkpoint","volume":"10","author":"Khanna","year":"2006","journal-title":"Cancer Cell"},{"key":"39","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/sj.cdd.4400851","article-title":"Characterization of the necrotic cleavage of poly(ADP-ribose) polymerase (PARP-1): implication of lysosomal proteases","volume":"8","author":"Poirier","year":"2001","journal-title":"Cell Death Differ"},{"key":"40","first-page":"a008656","article-title":"Caspase functions in cell death and disease","volume":"5","author":"Mak","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"41","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1158\/1078-0432.CCR-11-2824","article-title":"mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas","volume":"18","author":"Gutkind","year":"2012","journal-title":"Clin Cancer Res"},{"key":"42","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1158\/0008-5472.CAN-07-6696","article-title":"Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1","volume":"68","author":"Aggarwal","year":"2008","journal-title":"Cancer Res"},{"key":"43","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nature14129","article-title":"Comprehensive genomic characterization of head and neck squamous cell carcinomas","volume":"517","author":"Grandis","year":"2015","journal-title":"Nature"},{"key":"44","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1158\/2159-8290.CD-13-0103","article-title":"Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers","volume":"3","author":"Wang","year":"2013","journal-title":"Cancer Discov"},{"key":"45","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.oraloncology.2008.07.011","article-title":"Dysregulated molecular networks in head and neck carcinogenesis","volume":"45","author":"Gutkind","year":"2009","journal-title":"Oral Oncol"},{"key":"46","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1158\/1541-7786.MCR-07-0208","article-title":"Transforming growth factor-beta 1 promotes matrix metalloproteinase-9-mediated oral cancer invasion through snail expression","volume":"6","author":"Munshi","year":"2008","journal-title":"Mol Cancer Res"},{"key":"47","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/djm268","article-title":"Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1","volume":"100","author":"Hinz","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1471-2164-9-69","article-title":"Transcriptomic dissection of tongue squamous cell carcinoma","volume":"9","author":"Zhou","year":"2008","journal-title":"BMC Genomics"},{"key":"49","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1074\/jbc.273.2.871","article-title":"The TIMP2 membrane type 1 metalloproteinase \u2018receptor\u2019 regulates the concentration and efficient activation of progelatinase A. A kinetic study","volume":"273","author":"Murphy","year":"1998","journal-title":"J Biol Chem"},{"key":"50","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/0277-5379(88)90335-5","article-title":"Two new human tumor cell lines derived from squamous cell carcinomas of the tongue: establishment, characterization and response to cytotoxic treatment","volume":"24","author":"Lalanne","year":"1988","journal-title":"Eur J Cancer Clin Oncol"},{"key":"51","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1158\/1535-7163.MCT-10-0312","article-title":"Small interfering RNA targeting 14-3-3zeta increases efficacy of chemotherapeutic agents in head and neck cancer cells","volume":"9","author":"Siu","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"52","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1242\/jcs.072223","article-title":"MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance","volume":"124","author":"Peng","year":"2011","journal-title":"J Cell Sci"},{"key":"53","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1161\/HYPERTENSIONAHA.111.203489","article-title":"MicroRNA-376c impairs transforming growth factor-beta and nodal signaling to promote trophoblast cell proliferation and invasion","volume":"61","author":"Peng","year":"2013","journal-title":"Hypertension"},{"key":"54","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1038\/onc.2011.127","article-title":"Nodal enhances the activity of FoxO3a and its synergistic interaction with Smads to regulate cyclin G2 transcription in ovarian cancer cells","volume":"30","author":"Peng","year":"2011","journal-title":"Oncogene"},{"key":"55","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bjc.6602678","article-title":"REporting recommendations for tumour MARKer prognostic studies (REMARK)","volume":"93","author":"Clark","year":"2005","journal-title":"Br J Cancer"},{"key":"56","doi-asserted-by":"crossref","first-page":"e19213","DOI":"10.1371\/journal.pone.0019213","article-title":"Overexpression of prothymosin alpha predicts poor disease outcome in head and neck cancer","volume":"6","author":"Siu","year":"2011","journal-title":"PLoS One"},{"key":"57","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/ijc.28473","article-title":"S100A7 overexpression is a predictive marker for high risk of malignant transformation in oral dysplasia","volume":"134","author":"Ralhan","year":"2014","journal-title":"Int J Cancer"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.7751","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T19:08:31Z","timestamp":1589224111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.7751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,26]]},"references-count":57,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2016,3,29]]}},"alternative-id":["7751","26934445"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.7751","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,26]]}}}